GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Equity-to-Asset

China Pharma Holding (China Pharma Holding) Equity-to-Asset : 0.45 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. China Pharma Holding's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7.46 Mil. China Pharma Holding's Total Assets for the quarter that ended in Dec. 2023 was $16.47 Mil. Therefore, China Pharma Holding's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.45.

The historical rank and industry rank for China Pharma Holding's Equity-to-Asset or its related term are showing as below:

CPHI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24   Med: 0.56   Max: 0.77
Current: 0.45

During the past 13 years, the highest Equity to Asset Ratio of China Pharma Holding was 0.77. The lowest was 0.24. And the median was 0.56.

CPHI's Equity-to-Asset is ranked worse than
67.34% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs CPHI: 0.45

China Pharma Holding Equity-to-Asset Historical Data

The historical data trend for China Pharma Holding's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding Equity-to-Asset Chart

China Pharma Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.38 0.27 0.24 0.45

China Pharma Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.27 0.28 0.40 0.45

Competitive Comparison of China Pharma Holding's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Pharma Holding's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Equity-to-Asset falls into.



China Pharma Holding Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

China Pharma Holding's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=7.455/16.469
=0.45

China Pharma Holding's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=7.455/16.469
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Pharma Holding  (OTCPK:CPHI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


China Pharma Holding Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


China Pharma Holding (China Pharma Holding) Business Description

Traded in Other Exchanges
N/A
Address
Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Executives
Ke Deng 10 percent owner NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung officer: Chief Financial Officer 72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett director 4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang director NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong director NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui director, 10 percent owner FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li officer: President and CEO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang officer: Secretary NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu officer: CFO 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond 10 percent owner 174 FM 1830, ARGYLE TX 76226
David F Brigante 10 percent owner 174FM 1830, ARGYLE TX 76226
Marat Rosenberg 10 percent owner 17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp 10 percent owner 174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc 10 percent owner 174 FM 1830, ARGYLE TX 76226
Timothy P Halter director, 10 percent owner, officer: CEO, President & CFO 174 FM 1830, ARGYLE TX 76226